NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
21 sept. 2023 07h00 HE
|
NewAmsterdam Pharma N.V
-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”), respectively, indicating potential improvement of cholesterol metabolism in the brain -- --...
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
20 sept. 2023 08h00 HE
|
NewAmsterdam Pharma N.V
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical...
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
14 août 2023 16h01 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
07 août 2023 07h15 HE
|
NewAmsterdam Pharma Company B.V.
-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C (p<0.0001) -- --...
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
09 juin 2023 16h01 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, The Netherlands and MIAMI, June 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
06 juin 2023 23h25 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, The Netherlands and MIAMI, June 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company...
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
05 juin 2023 07h00 HE
|
NewAmsterdam Pharma Company B.V.
-- Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0%...
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
03 juin 2023 12h15 HE
|
NewAmsterdam Pharma Company B.V.
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55...
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
31 mai 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, May 31, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on...
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
23 mai 2023 08h00 HE
|
NewAmsterdam Pharma Company B.V.
NAARDEN, the Netherlands and MIAMI, May 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the...